Related Experiment Video
Updated: Jun 15, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Nichola Cruickshanks1, Leroy Shervington, Rahima Patel
1Brain Tumour North West, Faculty of Science and Technology, University of Central Lancashire, Preston, United Kingdom.
Abstract:
Hsp90alpha's vital role in cell cycle progression and apoptosis together with its presence in gliomas and absence in normal tissue, make it a credible target for cancer therapy. Three sets of dsRNA oligos designed to align different regions of the hsp90alpha sequence were used to downregulate hsp90alpha. SiRNA 1, 2, and 3 resulted in significant levels of silencing of hsp90alpha after 48 hr treatment (p < .0001). Concurrent treatment of the glioma cell line U87-MG with siRNA 1 and temozolomide (TMZ) resulted in a 13-fold reduction in the dose of TMZ required to achieve a similar effect if TMZ was used alone.
Insights
Heat shock protein 90 alpha (Hsp90alpha) is a promising target for glioma cancer therapy. Downregulating Hsp90alpha with siRNA enhanced the efficacy of temozolomide, reducing the required dose by 13-fold.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Heat shock protein 90 alpha (Hsp90alpha) plays a crucial role in cell cycle regulation and apoptosis.
- Hsp90alpha is frequently overexpressed in gliomas but absent in normal tissues, identifying it as a potential therapeutic target.
Purpose of the Study:
- To investigate the potential of Hsp90alpha as a therapeutic target in glioma.
- To evaluate the efficacy of small interfering RNA (siRNA) in downregulating Hsp90alpha expression.
- To assess the combined effect of Hsp90alpha downregulation and temozolomide (TMZ) treatment on glioma cells.
Main Methods:
- Three distinct small interfering RNA (siRNA) sequences targeting different regions of the hsp90alpha gene were designed.
- Glioma cell line U87-MG was treated with siRNA to assess Hsp90alpha silencing.
- Cells were concurrently treated with siRNA and varying doses of temozolomide (TMZ) to evaluate synergistic effects.
Main Results:
- All three siRNA sequences effectively silenced Hsp90alpha expression in U87-MG cells within 48 hours (p < .0001).
- Concurrent treatment with siRNA targeting Hsp90alpha and TMZ resulted in a significant 13-fold reduction in the effective dose of TMZ required to inhibit glioma cell growth.
Conclusions:
- Hsp90alpha is a viable therapeutic target for glioma treatment.
- siRNA-mediated Hsp90alpha silencing potentiates the anti-cancer effects of temozolomide in glioma.
- Combination therapy involving Hsp90alpha inhibition and TMZ holds promise for improved glioma treatment strategies.
